Skip to main content

Advertisement

Table 2 Univariate and multivariate analysis of survival for ER and PgR subgroups

From: Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer

Subgroups Cohort 1: BCSS Cohort 2: RFS Cohort 3: RFS Cohort 4: DRFS
  HR (95 % CI) P1 P2 HR (95 % CI) P1 P2 HR (95 % CI) P1 P2 HR (95 % CI) P1 P2
  Univariate Adjusteda    Univariate Adjusteda    Univariate Adjustedb    Univariate Adjustedc   
ER+/PgR+ 1 (ref.) 1 (ref.) <0.001d   1 (ref.) 1 (ref.) <0.001d   1 (ref.) 1 (ref.) 0.006d   1 (ref.) 1 (ref.) <0.001d  
ER−/PgR+ 4.67 (2.55–8.57) 3.26 (1.71–6.22) <0.001 <0.001 2.76 (1.27–5.99) 2.61 (1.20–5.67) 0.017 0.016 2.51 (1.11–5.68) 2.68 (1.10–6.55) 0.028 0.030 0.78 (0.19–3.27) 1.09 (0.26–4.64) 0.79 0.90
ER−/PgR− 7.26 (6.10–8.64) 4.12 (3.33–5.09) <0.001 <0.001 3.65 (2.71–4.92) 4.10 (3.03–5.54) <0.001 <0.001 2.59 (1.36–4.93) 2.51 (1.21–5.20) 0.003 0.013 3.33 (2.16–5.15) 3.66 (2.15–6.23) <0.001 <0.001
  1. Here we provided both unadjusted and adjusted values of HR of BCSS/RFS/DRFS to show the survival effect of ER/PgR status
  2. P1: Pairwise P value for univariate analysis (by log-rank test). ER+/PgR+ group as reference
  3. P2: Pairwise P value for multivariate analysis (by Cox regression). ER+/PgR+ group as reference
  4. BCSS Breast cancer-specific survival, CI Confidence interval, DRFS Distant relapse-free survival, HR Hazard ratio, ref Reference, RFS Relapse-free survival
  5. aAdjusted for age, tumor size, lymph nodes status, and grade
  6. bAdjusted for age, lymph nodes status, and grade. Tumor size is not adjusted because only half of cases have available information on it
  7. cAdjusted for age, tumor size, lymph nodes status, grade, and pathological complete response
  8. dOverall P value for univariate analysis (by log-rank test)